INTRODUCTION TO AMH {#sec1-1}
===================

Anti-Müllerian hormone (AMH), also known as Müllerian-inhibiting substance (MIS), is a Sertoli cell-secreted protein that plays a major role in the development of internal male genitalia.[@ref1] High expression of AMH in male gonads at the critical stage of embryonic genital development, *i.e*., 7 weeks of gestation,[@ref2][@ref3] promotes regression of the Müllerian duct. In the absence of AMH, Müllerian ducts develop into female internal sex organs. Anti-Müllerian hormone is named based on these processes. AMH is a dimeric glycoprotein consisting of two identical 70-kDa subunits and constitutes the transforming growth factor-beta (TGF-β) superfamily together with inhibins, activins, bone morphogenetic proteins (BMPs), and growth differentiation factors (GDFs). TGF-β family members play important roles in the regulation of cell proliferation and apoptosis in many biological processes, including folliculogenesis and spermatogenesis.

ROLE OF AMH IN SERTOLI CELL PHYSIOLOGY {#sec1-2}
======================================

Sertoli cells are the earliest cell type that appear in the embryonic testis.[@ref4][@ref5] More than 75% of the gonadal mass in the prepubertal testis is composed of Sertoli cells.[@ref6][@ref7] Dysfunction of Sertoli cell proliferation or maturation may lead to secretory dysfunction via endocrine and paracrine signaling, leading to an inability to support spermatogenesis. During fetal life, AMH is exclusively secreted by Sertoli cells and can be used as a functional marker of fetal Sertoli cells.[@ref1] Sertoli cells secrete other proteins that include (1) inhibins and activins, which are secreted by adult Sertoli cells to regulate follicle-stimulating hormone (FSH) production; (2) androgen-binding proteins (ABPs), which act as carrier proteins of testosterone and are responsible for the high concentration of intratesticular testosterone necessary for spermatogenesis;[@ref8] (3) estradiol, which is transformed from testosterone catalyzed by aromatases in Sertoli cells; and (4) glial cell line-derived neurotrophic factors (GDNFs), which contribute to the self-renewal of spermatogonial stem cells. All of these factors secreted by Sertoli cells are involved in spermatogenesis.[@ref9][@ref10][@ref11] Furthermore, Sertoli cells, rather than germ cells, express the androgen receptor,[@ref11] which is critical for the regulation of spermatogenesis induced by high concentrations of intratesticular testosterone.[@ref12]

 {#sec2-1}

### FSH is responsible for AMH transcriptional activation and the increase of Sertoli cell number in the absence of androgen signaling {#sec3-1}

The germ cell number in adult men depends on the number of Sertoli cells produced during perinatal development.[@ref5][@ref13] FSH has been recognized as a regulator of Sertoli cell number in developing testes.[@ref14][@ref15] The hypothalamic--pituitary--gonadal (HPG) axis is inactive in prepuberty, as demonstrated by low levels of both testosterone and gonadotropins.[@ref1][@ref16][@ref17][@ref18][@ref19] Lukas-Croisier *et al.*[@ref20] used a prepubertal FSH-deficient (FSH^-/-^) transgenic male mouse model to demonstrate that FSH transcriptionally activates AMH production in the absence of androgen signaling. They showed that serum AMH concentration, Sertoli cell number, and testicular volume were decreased in *FSH* knockout mice and returned to normal after administration of recombinant FSH and transfection of FSH receptor plasmid. They next transfected different fragments of *AMH* promoter regions, together with the FSH receptor gene, into a prepubertal Sertoli cell line and added recombinant FSH protein to activate *AMH* transcription. The results showed that FSH transcriptionally activates *AMH* through a nonclassical cyclic adenosine monophosphate (cAMP) pathway by binding to the *AMH* promoter region located more than -1.9 kb away from the transcription initiation site at nuclear factor kappa-B (NF-κB) and transcription factor AP2-binding sites.[@ref20] Unlike the distal regulation of the *AMH* promoter region by NF-κB, regulation of the proximal promoter of *AMH* has been extensively studied. Sex-determining region Y box 9 (Sox9),[@ref21][@ref22] steroidogenic factor-1 (SF1),[@ref23][@ref24][@ref25] and GATA factors[@ref26][@ref27] are implicated in the transcriptional activation of *AMH* within -220 bp of the transcriptional start site independent of gonadotropic control.[@ref28][@ref29] A schematic diagram of FSH-regulated *AMH* transcriptional activation is shown in **[Figure 1](#F1){ref-type="fig"}**. Another study using Tfm mice with a mutation in the androgen receptor gene that made the XY mouse insensitive to androgens[@ref30][@ref31] showed that FSH administration resulted in the elevation of serum AMH levels in the absence of androgen signaling.[@ref32] FSH-induced *AMH* transcription and an increase in Sertoli cell number were also observed in neonates and adult humans suffering from hypogonadotropic hypogonadism (HH).[@ref6][@ref16][@ref33] The androgen signaling pathway of these individuals is not functional, and their decreased AMH levels return to normal after the administration of recombinant FSH.

![Schematic diagram of FSH-regulated AMH transcriptional activation. FSH: follicle-stimulating hormone; FSHR: FSH receptor; AC: adenylate cyclase; NF-κB: nuclear factor kappa-B; IκB: NF-κB inhibitor; SP1: transcription factor Sp1; GATA: GATA-binding proteins; SOX9: sex-determining region Y box 9; AMH: anti-Müllerian hormone; cAMP: cyclic adenosine monophosphate.](AJA-21-109-g001){#F1}

### Testosterone downregulates AMH expression {#sec3-2}

The most obvious example of negative regulation of AMH by testosterone is that when boys enter puberty, a sudden increase in their testosterone levels results in decreased levels of AMH, indicating that testosterone has an inhibitory effect on AMH;[@ref34] the increase in intratesticular testosterone levels is responsible for the inhibition of AMH levels.[@ref32][@ref35][@ref36][@ref37] Another example is the increase in testosterone levels in precocious children, which is always accompanied by a decrease in AMH levels regardless of gonadotropin dependence or independence.[@ref18] This negative regulatory pattern can also explain hormone levels in patients with androgen insensitivity syndrome (AIS) caused by mutations in the androgen receptor gene. The diagnosis of AIS is made by detecting normal-to-high testosterone and AMH levels and the absence of Müllerian derivatives in 46, XY males;[@ref28][@ref38][@ref39][@ref40] the high levels of testosterone do not induce a decrease in AMH levels due to androgen signaling dysfunction.

Animal experiments also revealed a pattern of negative regulation between testosterone and AMH. The knockout of androgen receptors in Sertoli cells in mice induces a significant decrease in testosterone levels and thus gives rise to transiently elevated expression of AMH at both the mRNA and protein levels in Sertoli cells.[@ref41] How does testosterone inhibit the expression of AMH? Another study performed the following mechanistic investigation to show that binding at the NF-κB-binding site in the distal promoter region of *AMH* provides transcriptional activity levels higher than those produced by binding at the SP1-, GATA-, and Sox9-binding sites in the proximal promoter regions.[@ref20] Although there are no androgen receptor-binding sites in the *AMH* promoter region,[@ref42] there are NF-κB binding sites, and NF-κB is negatively regulated by androgen receptors;[@ref43][@ref44] therefore, although testosterone cannot directly regulate *AMH* transcription, it can fulfill its function by inhibiting the transcription of *NF-κB* and thus suppress the transcriptional activation of *AMH*.

However, AMH levels are not always negatively regulated by testosterone because of defects in androgen signaling. For instance, a synchronous increase in AMH and testosterone levels was discovered in neonates.[@ref36][@ref45] It was discovered that the androgen receptor is present in fetal and neonatal Leydig and peritubular cells but not in Sertoli cells.[@ref46][@ref47] The absence of androgen receptor expression in fetal and neonatal Sertoli cells may contribute to the lack of transcriptional suppression of *AMH*. Thus, FSH-induced *AMH* transcriptional activation and luteinizing hormone (LH)-induced testosterone activation account for the main biological events in fetal and neonate boys.

ASSOCIATIONS BETWEEN SERUM AMH AND DISORDERS RELATED TO MALE FERTILITY {#sec1-3}
======================================================================

 {#sec2-2}

### Diagnosis and differential diagnosis of disorders of sex development (DSD) {#sec3-3}

Male genital differentiation is driven by two hormones: testosterone, which is produced by fetal Leydig cells, maintains Wolffian ducts, and contributes to the virilization of external genitalia, and AMH, which is produced by fetal Sertoli cells and is responsible for the regression of fetal Müllerian ducts.[@ref48] DSD in males may result from defects in the signaling of one or both of these hormones. Dysfunction of secretion or an inactive state of AMH, caused by mutations in *AMH* or its receptor *AMHRII*, leads to persistent Müllerian duct syndrome (PMDS). Patients with PMDS are born male according to the general human standard at birth, but the Müllerian duct derivatives persist, manifested as undescended testes (cryptorchidism) and the presence of a small, underdeveloped uterus in an XY infant or adult. Notably, fertility in PMDS patients is rare but possible if at least one testis descends to the scrotum with its excretory ducts intact.[@ref49] No external genital ambiguity, especially without hypospadias, is the main feature of PMDS that distinguishes it from mixed gonadal dysgenesis, which is an early-onset complete type of DSD with fetal hypogonadism resulting from the dysfunction of both Leydig and Sertoli cells.[@ref28]

Recently, mutations in the *AMH* and its receptor gene were found to account for 88% of PMDS cases in which undescended testes (UDTs) are the clinical manifestation.[@ref49] The remaining 12% of PMDS cases are idiopathic, and no mutations in *AMH* or *AMHRII* have been detected. However, we cannot rule out the possibility of *AMH* or *AMHRII* mutations, as some studies have shown that the diversity of *AMH* or *AMHRII* mutations might be underrecognized and that the sensitivity and specificity of sequencing can be limited,[@ref49] leading to unidentified mutations in the distal promoter or introns of *AMH* or *AMHRII*. Furthermore, we cannot rule out the possibility of mutations in other molecules in the AMH signaling pathway.

PMDS should be distinguished from other types of UDT. Leydig cell function in patients with PMDS is generally normal,[@ref49] as indicated by normal levels of serum testosterone and LH.[@ref17][@ref49] The levels of inhibin B, secreted by Sertoli cells,[@ref50][@ref51][@ref52] are normal in boys with *AMH* mutations but undetectable in boys with *AMHRII* mutations.[@ref17] Serum AMH levels depend on the molecular origin of *AMH* or *AMHRII* mutations. Very low or undetectable circulating AMH levels in prepubertal boys or adults with PMDS are characteristics of mutations in *AMH*, resulting in a lack of AMH protein secretion. Meanwhile, normal serum AMH levels are detected in boys with *AMHRII* mutations. Congenital adrenal hyperplasia (CAH) in females (46, XX) with a male phallus and bilateral nonpalpable gonads should first be differentially diagnosed from UDT via its severe complications, such as hyponatremia, hyperkalemia, and shock. When increasing severity of hypospadias with UDT is discovered, the possibility of a mixed DSD should be considered.[@ref53] In patients with mixed types of DSD accompanied by low serum levels of both AMH and testosterone and external genital malformations, low AMH reflects severe testicular dysgenesis and should not be confused with PMDS. If an infant with bilateral nonpalpable testes has a 46, XY karyotype, an evaluation to distinguish anorchia from bilateral abdominal testes is needed to avoid surgical exploration. To assess the presence of testicular tissue, serum AMH should first be considered;[@ref53] other hormone tests include those that detect FSH, LH, inhibin B, and testosterone levels.[@ref53] A flowchart indicating the differential diagnosis of DSD is shown in **[Figure 2](#F2){ref-type="fig"}**.

![AMH contributes to the differential diagnosis of DSD. UDT: undescended testis; CAH: congenital adrenal hyperplasia; DSD: disorders of sex development; PMDS: persistent Müllerian duct syndrome; AMH: anti-Müllerian hormone; T: testosterone; AMHR: AMH receptor.](AJA-21-109-g002){#F2}

Studies of unilateral UDT revealed that UDTs in children are smaller than their descended counterparts (*P* \< 0.001).[@ref54][@ref55] Given that Sertoli cells account for 75% of testis mass in prepubertal males,[@ref6][@ref7] there may be varying degrees of decline in the number of Sertoli cells in UDT, which may result from increased temperature around the UDT. The degree of AMH decrease in boys bearing cryptorchidism is related to the severity of UDT injury,[@ref56][@ref57][@ref58] suggesting that deteriorated Sertoli cell function may be an early example of damage from UDT. Moreover, infertility is the major long-term concern of patients with a history of UDT.[@ref53] Infertility risks of 30% and 54% were discovered in unilateral and bilateral UDT, respectively,[@ref59][@ref60][@ref61][@ref62][@ref63] in accordance with the duration for which UDT is exposed to abdominal temperature. A 75%--100% risk of infertility was found in boys with bilateral UDT in whom no germ cells were found on biopsy.[@ref64] In conclusion, the degree of male infertility caused by UDT is related to the severity of injury to Sertoli cells; thus, a higher degree of serum decline in AMH in boys may suggest a greater risk of infertility when they become adults.

### Distinguishing pubertal delay from congenital hypogonadotropic hypogonadism {#sec3-4}

Constitutional pubertal delay and congenital HH share the same clinical manifestation of delayed sexual maturation in prepubertal boys. Levels of gonadotropin and testosterone are very low in prepubertal boys and therefore have little clinical significance; thus, AMH, the marker of Sertoli cells, is of great importance in the differential diagnosis of constitutional pubertal delay and congenital HH.[@ref18][@ref46]

Congenital HH is often accompanied by Sertoli cell dysfunction.[@ref65] Severe deficiency in gonadotropin levels in congenital HH patients results in a decreased number of Sertoli cells and correspondingly low levels of AMH and inhibin B.[@ref65][@ref66][@ref67] The constitutional delay of puberty reflects a eugonadal state of Sertoli cells, and serum AMH is within the normal level for prepubertal boys.[@ref68] In patients with untreated congenital HH, the AMH level is increased upon administration of recombinant FSH due to FSH-induced proliferation of Sertoli cells, whereas further treatment with human chorionic gonadotropin (hCG) gives rise to a decline in AMH levels due to the hCG-induced increased levels of testosterone, which induces inhibition of *AMH* that overrides FSH-initiated *AMH* transcription. However, the administration of exogenous testosterone did not result in a decrease in AMH concentrations, which may be caused by low intratesticular testosterone levels in congenital HH patients.

### Nonobstructive azoospermia and Klinefelter syndrome (47, XXY) {#sec3-5}

Nonobstructive azoospermia (NOA) is the most severe type of male infertility, characterized by a lack of sperm in semen induced by impaired spermatogenesis.[@ref69] Increased serum FSH, decreased serum AMH and inhibin B, have been discovered in men with NOA.[@ref70][@ref71][@ref72] With the advent of intracytoplasmic sperm injection (ICSI) technology, these NOA patients also have the opportunity to have their own children through testicular sperm extraction (TESE) or microdissection-testicular sperm extraction (MD-TESE), with sperm recovery rates (SRRs) of only 40%--60%.[@ref69][@ref73] Currently, there are no acknowledged markers of SRR with good sensitivity and specificity. FSH, inhibin B, AMH, and testosterone, although differentially expressed in NOA, are not good predictors of SRR. Higher baseline testosterone,[@ref74] lower FSH,[@ref75] higher AMH,[@ref76] or higher inhibin B[@ref77] levels do not guarantee a better SRR in NOA patients. The underlying mechanism may be the following: the function of the Sertoli cells and interstitial cells is impaired, as indicated by abnormal hormone levels, but not completely lost in a large number of NOA patients; spermatogenesis is only present in small areas, if any.[@ref78] In our clinical practice, we have identified a certain number of NOA patients whose serum AMH levels are below the lower limit of the male reference interval or even undetectable and whose serum testosterone levels are normal or subnormal yet obtain good pregnancy outcomes using their own sperm retrieved via TESE or MD-TESE. These serum markers may be useful when combined with testicular volume, age and other markers to predict SRR before TESE or MD-TESE using a multivariable regression method.[@ref77][@ref79]

Klinefelter syndrome is characterized by accelerated germ cell depletion[@ref80] and occurs in approximately 10%--12% of NOA men.[@ref81] In patients with Klinefelter syndrome, circulating AMH levels are within the reference range until puberty; thereafter, AMH declines to subnormal concentrations in adults.[@ref82][@ref83] In a 12.3-year follow-up study of 29 patients with Klinefelter syndrome, an early increase in FSH was detected, accompanied by abnormally low or undetectable levels of AMH and inhibin B in advanced pubertal stages, which may be explained by progressive impairment of endocrine function during childhood and puberty.[@ref83] However, a delay in the puberty-related decline of AMH was observed in patients with Klinefelter syndrome, finally leading to decreased AMH levels in adulthood,[@ref82] which may be caused by temporary functional compensation of Sertoli cells. Furthermore, in our clinical practice, we identified a few severe NOA patients, including severe Klinefelter syndrome patients, whose serum AMH and testosterone levels were both undetectable and with no sperm retrieved via MD-TESE, indicating that their germ cells were completely depleted. Undetectable AMH and testosterone were also used to distinguish anorchia from UDT,[@ref84][@ref85][@ref86] as shown in **[Figure 2](#F2){ref-type="fig"}**, implying that in male adults, undetectable serum AMH and testosterone can be used to assess whether any functional testicular tissue or, specifically, functional germ cells exist.

### Varicocele {#sec3-6}

Varicocele is an abnormal enlargement and bending of the pampiniform venous plexus in the scrotum. The adverse effects of varicocele on spermatogenesis are progressive and therefore decrease male fertility with time. Expansion of the veins impairs the testicular blood supply, resulting in a reduction in the oxygenated blood and nutrient supply to the local testis, which leads to a decline in the quality and quantity of sperm; on the other hand, it also induces dysfunction of the testicular nervous plexus, the main function of which is to regulate testicular temperature. Higher testicular temperatures can lead to testicular atrophy and infertility. Indeed, varicocele is the main cause of male infertility,[@ref87] and it was found in approximately 35% of primary infertile men and 81% of secondary infertile men.[@ref88]

The severe damage caused by varicocele is correlated with impaired function of Sertoli cells. According to the study from Li *et al.*,[@ref89] the levels of transferrins and androgen-binding proteins secreted by Sertoli cells were reported to be downregulated in patients suffering from varicocele, suggesting that decreased testicular blood flow may lead to impaired function of Sertoli cells. Furthermore, testicular biopsies in patients with varicocele showed that the germ cells in the seminiferous tubule were sloughed, and this phenomenon was often associated with impaired Sertoli cell function.[@ref90]

An analysis of serum AMH levels in varicocele-bearing patients was inconclusive. A study in adult subfertility men including varicocele, idiopathic NOA, idiopathic nonobstructive dyspermia, cryptorchidism, and other diagnoses indicated that circulating AMH levels in subfertile men were 60% lower than those in corresponding controls, accompanied by a decreased level of inhibin B, indicating the decreased function of Sertoli cells in varicocele-bearing adult patients.[@ref91] In prepubertal and pubertal boys with varicocele, AMH concentrations were elevated, accompanied by an increase in inhibin B levels, suggesting a compensatory increase in Sertoli cell function in the early-onset varicocele.[@ref92] There was also an article reporting a lower concentration of AMH in the local spermatic vein than in the peripheral blood, suggesting that poor blood supply in patients with varicocele causes the deterioration of Sertoli cell function.[@ref93]

### McCune-Albright syndrome in boys {#sec3-7}

As we mentioned previously, normal puberty is accompanied by decreased serum levels of AMH. However, in boys with McCune-Albright syndrome, precocious puberty is observed, but abnormal increased instead of decreased levels of AMH are detected,[@ref94][@ref95][@ref96] accompanied by macro-orchidism and androgen-dependent secondary sexual defects. Hyperfunction of Sertoli cells without Leydig cell activation was reported to be responsible for the onset of this disease.[@ref97]

### Male senescence {#sec3-8}

Testes, hormone production, and spermatogenesis undergo senescence as a man ages.[@ref98] Johnson *et al.*[@ref99] identified an age-related decrease in Sertoli cell number; consistent with this, AMH, as a marker of immature Sertoli cells, was also found to be reduced with increasing age[@ref36][@ref100][@ref101] and negatively correlated with FSH and LH, which indicates that decreased AMH levels as a man ages represent age-related reduced Sertoli cell function.

CONCLUSION {#sec1-4}
==========

In the absence of androgen signaling, FSH promotes *AMH* transcription by activating the -1.9 kb *AMH* promoter region, where NF-κB has the highest level of transcriptional activation activity, and the proximal within -220 bp[@ref20] *AMH* promoter region, where Sox9,[@ref21][@ref22] SF1,[@ref23][@ref24][@ref25] and GATA factors[@ref25][@ref26][@ref27] reside. Testosterone inhibits the transcriptional activation of *AMH*, hypothetically through transcriptional inhibition of *NF-κB*. Regarding the associations between serum AMH and disorders related to male fertility, undetectable serum AMH and testosterone indicate a lack of functional testicular tissue, for example, that in patients with anorchia or severe Klinefelter syndrome suffering from impaired spermatogenesis. Normal serum testosterone levels and undetectable AMH are highly suggestive of PMDS. The levels of both AMH and testosterone are always subnormal in patients with mixed DSD (as shown in **[Figure 2](#F2){ref-type="fig"}**). The usefulness of AMH levels in these conditions (pubertal delay, severe congenital HH, NOA, Klinefelter, varicocele, McCune-Albright syndrome, and male senescence) is also summarized, as indicated in **[Table 1](#T1){ref-type="table"}**.

###### 

Anti-Müllerian hormone levels in disorders related to male fertility

  *Categories*                    *AMH level*
  ------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------
  Pubertal delay                  Normal prepubertal level in puberty
  Severe congenital HH            Decreased in puberty
  Klinefelter syndrome (47,XXY)   Within the reference range until puberty; a delay in puberty-related decline; thereafter, declined to subnormal concentrations in adults
  NOA                             Decreased AMH level
  Varicocele                      Elevated in early-onset varicocele in prepubertal and pubertal boys, and decreased in adults with severe varicocele
  McCune-Albright syndrome        Increased AMH level in boys
  Male senescence                 Age-related decrease

HH: hypogonadotropic hypogonadism; NOA: nonobstructive azoospermia; AMH: anti-Müllerian hormone
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